Novel HER2-targeted gold nanoparticles for gastric cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 26870390
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy; Digestive surgery
• Research Institution: Okayama University
• Principal Investigator: Kuroda Shinji 岡山大学, 医学部, 客員研究員 (60633758)
• Research Collaborator: KUBOTA Tetsushi 岡山大学大学院医歯薬学総合研究科, 消化器外科学, 大学院生
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 金ナノ粒子 / トラスツズマブ / HER2 / 胃癌 / トラスツズマブ抵抗性

Outline of Final Research Achievements

Trastuzumab (Tmab)-conjugated gold nanoparticles (Tmab-AuNP) showed strong cytotoxic effect on a Tmab-resistant HER2-positive gastric cancer cell line while Tmab did not. On a HER2-negative gastric cancer cell line, Tmab-AuNP showed strong cytotoxic effect after HER2 extra-cellular domain was over-expressed on the cell surface. These specific cytotoxic activity of Tmab-AuNP was produced through increase of oxidative stress and autophagy induced after intracellular uptake of Tmab-AuNP. These findings demonstrated that Tmab-AuNP could be a novel intriguing therapeutic agent for Tmab-resistant cancers.

Free Research Field

消化器外科